Skip to main content

Table 6 Logistic regression analysis predicting a last PSA value of <0.2 ng/mL in patients with a normal testosterone level at the last follow-up (after at least 4 years)

From: Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer

 

univariate

multivariate

variables

OR

95%C.I.

P-value

OR

95%C.I.

P-value

IMRT (reference) vs. BT

9.840

5.681–17.041

<0.001

5.032

1.911–13.253

0.001

PSA

-10 ng/mL

reference

    

n.s.

10-20 ng/mL

0.766

0.459–1.277

0.306

   

20 ng/mL-

0.202

0.096–0.426

<0.001

   

BED

-160Gy2

reference

  

reference

  

160-180Gy2

7.040

3.546–13.977

<0.001

2.753

1.017–7.450

0.046

180Gy2-

8.038

4.800–13.459

<0.001

2.859

1.184–6.903

0.020

Age

−64

reference

  

reference

  

65–74

1.666

1.017–2.730

0.043

2.679

1.524–4.709

0.001

75-

1.498

0.819–2.742

0.190

2.956

1.444–6.053

0.003

Risk (D’Amico)

Low

reference

    

n.s.

Intermediate

0.982

0.604–1.597

0.941

   

High

0.445

0.255–0.778

0.004

   

ADT use

none

reference

    

n.s.

Neoad+

0.729

0.450–1.183

0.201

   

Ad+

0.290

0.070–1.197

0.087

   

Neoad+/Ad+

0.326

0.175–0.610

<0.001

   
  1. OR odds ratio, C.I confidential interval, IMRT intensity modulated radiation therapy, BT brachytherapy, PSA prostate specific antigen, BED biological effective dose, ADT androgen deprivation therapy, Neoad neoadjuvant, Ad adjuvant